Triumeq ([dolutegravir + abacavir + lamivudine]; ViiV Healthcare) is a single-tablet regimen (STR) for the treatment of HIV-1 infection. It is a co-formulation of the marketed HIV drugs Tivicay (dolutegravir; ViiV Healthcare) and Epzicom ([abacavir + lamivudine]; ViiV Healthcare), which is known as Kivexa outside the US. Tivicay is an integrase inhibitor that blocks the insertion of the viral genome into the host genome, and Epzicom is a fixed-dose combination nucleoside reverse transcriptase inhibitor that prevents viral RNA replication.
Triumeq is the first and only single-tablet regimen to have demonstrated a superior rate of virologic suppression compared to Atripla ([efavirenz + emtricitabine + tenofovir disoproxil fumarate (TDF)]; Gilead). Its strong efficacy, attractive tolerability profile, and the high barrier to resistance offered by its Tivicay (dolutegravir; ViiV Healthcare) component have resulted in Triumeq generating blockbuster worldwide sales of $3.4bn in 2018. However, multiple factors limit its future growth potential, including intense competition from Gilead’s rival integrase strand transfer inhibitor-containing STR Biktarvy ([bictegravir + emtricitabine + tenofovir alafenamide (TAF)]), physician preference for the TAF + emtricitabine backbone, and the threat of generic incursion.
4 Drug Overview
5 Product Profiles
5 Triumeq : HIV
LIST OF FIGURES
10 Figure 55: Datamonitor Healthcare’s drug assessment summary of Truvada for HIV
11 Figure 56: Truvada sales for HIV across the US and five major EU markets, by country, 2018–27
14 Figure 57: Datamonitor Healthcare’s drug assessment summary of cabotegravir/rilpivirine for HIV
LIST OF TABLES
6 Table 1: Triumeq drug profile
6 Table 2: Approval history of Triumeq for HIV in the US, Japan, and five major EU markets
8 Table 3: Late-phase trials of Triumeq for HIV
9 Table 4: Triumeq for HIV – SWOT analysis
Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is Suite 1, 3rd Floor, 11 - 12 St. James's Square, London, England, SW1Y 4LB. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.